Sulfur Containing Patents (Class 554/85)
  • Patent number: 10532978
    Abstract: The present invention relates to a multi-step process for the production of dihydrolipoic acid, which can particularly be carried out as a one-pot reaction and without isolation of intermediates.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 14, 2020
    Assignee: ALZCHEM TROSTBERG GMBH
    Inventors: Ingo Schnapperelle, Stephan Winkler, Jürgen Sans, Franz Thalhammer
  • Patent number: 10343970
    Abstract: Polyol esters of metathesized fatty acids are generally disclosed herein. Methods of using such compounds, for example, as cleaning agents, solvents, and coalescents for paints and coatings, are also disclosed.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: July 9, 2019
    Assignee: Elevance Remewable Sciences, Inc.
    Inventor: Paul A. Bertin
  • Patent number: 9161928
    Abstract: Use of polyunsaturated fatty acid derivatives as medicaments or functional foods. The present invention relates to the use of 1,2-fatty acid derivatives in the treatment or prevention of common diseases whose etiology is based on alterations (of any type) of the cell membrane lipids, for example, changes in levels, in the composition or in the structure of these lipids. In addition, for diseases in which the regulation of lipid composition and of the structure of the membranes (or proteins that interact with membranes) causes the reversion of pathological state.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: October 20, 2015
    Assignee: Lipopharma Therapeutics, S.L.
    Inventors: Pablo Vicente Escriba Ruiz, Xavier Busquets Xaubet, Silvia Teres Jimenez, Gwendolyn Barcelo Coblijn, Victoria Llado Canellas, Amaia Marcilla Etxenike, Maria Laura Martin, Monica Higuera Urbano, Rafael Alvarez Martinez, Daniel Horacio Lopez
  • Patent number: 8895040
    Abstract: The present invention relates to cosmetic and/or personal care formulations and/or compounds. In one embodiment, the present invention relates to ester compounds that can be used in various personal care formulations and/or compounds. In another embodiment, the present invention relates to branced ester compounds having a molecular weight of at least about 1,500 daltons that can be used in various personal care formulations and/or compounds.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: November 25, 2014
    Assignee: Lubrizol Advanced Materials, Inc.
    Inventors: Brian J. Vondruska, Peter Frank, Anchuu Wu
  • Publication number: 20140335157
    Abstract: The present invention relates to a compound represented by the formula (1) wherein Xa and Xb are each independently X1 or X2; s is 1 or 2, R4 is an alkyl group having 1-6 carbon atoms, na and nb are each independently 0 or 1, R1a and R1b are each independently an alkylene group having 1-6 carbon atoms, R2a and R2b are each independently an alkylene group having 1-6 carbon atoms, Ya and Yb are each independently an ester bond, an amide bond, a carbamate bond, an ether bond or a urea bond, and R3a and R3b are each independently a sterol residue, a liposoluble vitamin residue or an aliphatic hydrocarbon group having 12-22 carbon atoms, and use thereof.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 13, 2014
    Inventors: Kota TANGE, Masaya ARAI, Kazuhiro KUBO, Hidetaka AKITA, Hideyoshi HARASHIMA, Hiroto HATAKEYAMA, Ryohei ISHIBA, Masami UKAWA, Hiroki TANAKA
  • Publication number: 20140256814
    Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 11, 2014
    Applicant: COMPLEXA, INC.
    Inventor: Raymond A. Miller
  • Patent number: 8759558
    Abstract: The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: June 24, 2014
    Assignee: Pronova Biopharma Norge AS
    Inventors: Anne Kristin Holmeide, Ragnar Hovland, Morten Brændvang
  • Patent number: 8686167
    Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: April 1, 2014
    Assignee: Complexa, Inc.
    Inventor: Raymond A. Miller
  • Publication number: 20140005423
    Abstract: Alkoxylated fatty ester compositions are disclosed. In one aspect, the compositions comprise a reaction product of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with one or more alkylene oxides in the presence of an insertion catalyst to give an alkoxylated fatty ester. In another aspect, the metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or its ester derivative is reacted with a glycol ether or a glycol ether alkoxylate, to give an alkoxylated fatty ester. In yet another aspect, the metathesis-derived C10-C17 monounsaturated acid or octadecene-1,18-dioic acid is reacted with one or more alkylene oxides to give a fatty acid alkoxylate, followed by etherification of the fatty acid alkoxylate.
    Type: Application
    Filed: October 25, 2011
    Publication date: January 2, 2014
    Applicant: Stepan Company
    Inventors: Dave R. Allen, Marcos Alonso, Randal J. Berhardt, Aaron Brown, Kelly Buchek, Sangeeta Ganguly-Mink, Brian Holland, Andrew D. Malec, Ronald A. Masters, Dennis S. Murphy, Patti Skelton, Brian Sook, Michael Wiester, Patrick Shane Wolfe
  • Publication number: 20130330401
    Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 12, 2013
    Applicant: Nitto Denko Corporation
    Inventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
  • Patent number: 8563760
    Abstract: This invention relates to processes for preparing long-chain fatty acids of Formula I: and salts thereof, as well as intermediates for the processes, wherein L1 and L2 are described herein.
    Type: Grant
    Filed: August 30, 2010
    Date of Patent: October 22, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Abdul H. Fauq, Albert O. Edwards
  • Publication number: 20130267723
    Abstract: Provided herein are compounds of the formula: wherein m is an integer greater than or equal to 1; n is an integer greater than or equal to 0; Z is selected from NR5, S, and O; Z? is, independently for each occurrence, selected from NR5, S, and O; R1 is, independently for each occurrence, is an optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; R5 is, independently for each occurrence, selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched; and R3 and R4, independently for each occurrence, are selected from optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched. Also provided are compositions containing the compounds and methods of making both the compounds and compositions thereof.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Inventors: Jeremy FOREST, Jakob BREDSGUARD
  • Publication number: 20130225837
    Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 29, 2013
    Applicants: Nippon Zoki Pharmaceutical Co., Ltd., Nagoya Industrial Science Research Institute
    Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
  • Publication number: 20130211114
    Abstract: A composition of the formulae MZAORSnR1F1mOAZ1M1, wherein O and S have their normal meaning of oxygen and sulfur, n is at least 2 and not more than 8, F1 is of the formula —OAORSnR1—, m is at least 1, Z and Z1 are the same or different and are oxy or amino, M and M1 are the same or different and are hydrogen or an organic substituent, R and R1 are the same or different and are organic divalent radicals, each having from 2 to 20 carbon atoms, and A is the residue of a dicarboxylic acid of from 2 to 40 carbon atoms.
    Type: Application
    Filed: January 30, 2013
    Publication date: August 15, 2013
    Applicant: POLYMERight, Inc.
    Inventor: POLYMERight, Inc.
  • Patent number: 8501972
    Abstract: A solid fatty acid alkyl ester sulfonate metal salt is disclosed having an endothermic peak area between 50° C. and 130° C. of 50% or more relative to the whole endothermic peak area between 0° C. and 130° C. when determined using a differential scanning calorimter. A method for producing a fatty acid alkyl ester sulfonate metal salt powder is also disclosed, including a step of pulverizing the solid fatty acid alkyl ester sulfonate metal salt in a pulverizer, with the internal temperature of the pulverizer being adjusted to 30° C. to 50° C.
    Type: Grant
    Filed: October 22, 2008
    Date of Patent: August 6, 2013
    Assignee: Lion Corporation
    Inventors: Yutaka Abe, Naoki Nakamura, Takao Matsuo, Daisuke Negishi, Hiroyuki Masui, Toru Yoshii, Nobukazu Shogase, Masahiko Matsubara
  • Patent number: 8278358
    Abstract: The invention describes alpha lipoic acid complexes, that can be oligomeric, polymeric, monomeric and mixtures thereof. The complexes can be salts, chelates, etc. of the oligomers, polymers, or monomeric alpha lipoic acid.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: October 2, 2012
    Assignee: Omnica GmbH
    Inventor: Thomas Eidenberger
  • Patent number: 8221734
    Abstract: Non-pressurized shaving compositions are described that provide a warm/hot sensation during use as the result of an exothermic redox reaction. The compositions are post-foaming via nascent gas release in situ due to the generation of carbon dioxide. The carbon dioxide induced foam is maintained for several minutes after the compositions are dispensed, whereby the compositions are capable of providing both a warm sensation and sustained lather, a balance which heretofore has been a significant challenge.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: July 17, 2012
    Assignee: The Procter & Gamble Company
    Inventors: Alexander Novikov, Uday Marutirao Patil, Robert John Willicut
  • Publication number: 20120041025
    Abstract: Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hypertension, diabetes, dyslipidemia, renal insufficiency, myocardial infarction, stroke, atherosclerosis, and the target organ damage that accompanies these various diseases and disorders, are further provided. The compounds are useful in improving vasodilation, reducing low-density lipoprotein oxidation, and reducing inflammation in a subject.
    Type: Application
    Filed: February 19, 2010
    Publication date: February 16, 2012
    Inventor: Sampath Parthasarathy
  • Publication number: 20120015865
    Abstract: A subject of the present invention is the development of a novel family of cationic lipids and their use as vectors for in vitro, ex vivo and in 5 vivo delivery of biologically active agents.
    Type: Application
    Filed: February 16, 2011
    Publication date: January 19, 2012
    Applicant: OZ BIOSCIENCES
    Inventors: Olivier Zelphati, Stéphane Moutard
  • Patent number: 7947757
    Abstract: The invention relates to an initiator comprising at least one structural element characterized by the following formula (I) wherein X? is a non or low coordinating anion, R1, R2, R3, R4 are independently linear, cyclic or branched C1-C20 alkyl or alkylene groups, wherein one or more of the methylene groups contained in the alkyl or alkylene group can be substituted by —CO—, —CONH—, —CON(CH3)—, —S— and/or —O—, and wherein R1, R2, R3 and/or R4 can act as a bridging element connecting two or more structural elements. The invention is also related to a process of producing the initiator and to a curable composition comprising the initiator, a process for producing the curable composition a kit comprising a cationically curable composition and the inventive initiator and the use of the initiator or the curable composition comprising the initiator for various applications, especially in the dental field.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: May 24, 2011
    Assignee: 3M Innovative Properties Company
    Inventors: Thomas Klettke, Cornelia B. Fuehrer, Andrea Hailand, Markus Mikulla
  • Publication number: 20110076499
    Abstract: A solid a-sulfo fatty acid alkyl ester salt having a bubble volume fraction of 1 to 15% is provided by introducing a gas into a paste of a-sulfo fatty acid alkyl ester salt or adding thereto an expanding agent to incorporate bubbles into the paste of a-sulfo fatty acid alkyl ester salt.
    Type: Application
    Filed: May 25, 2009
    Publication date: March 31, 2011
    Applicant: Lion Corporation
    Inventors: Hiroyuki Masui, Naoki Nakamura, Takao Matsuo
  • Patent number: 7880024
    Abstract: Provided are an ionic liquid and a method of preparing the same. The ionic liquid includes at least one type of compound represented by (Cat+)(R?COO?). Here, the Cat+ is a cation selected from the group consisting of quaternary ammonium, quaternary phosphonium, sulfonium, imidazolium, pyridinium, pyrazolium, piperidinium, pyrrolium, pyrrolidinium, triazolium, and a mixture of two or more thereof, and R? is a hydrocarbon comprising at least one unsaturated bond, and having 4 to 30 carbon atoms. The ionic liquid is partially or completely miscible with various polar and/or non-polar solvents, and may be used as a solvent, a solvent additive, an electrolyte, a heat carrier, a charge carrier, a heat carrier additive, a charge career additive, or a phase transfer catalyst, at room temperatures and below. Furthermore, the cost of manufacturing the ionic liquid can be reduced.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: February 1, 2011
    Assignee: Samsung Engineering Co., Ltd.
    Inventors: Myong Hoon Lim, Young Mi Kim, Jae Eun Rho, Jae Hoi Gu, Yong Ho Yu
  • Publication number: 20090247634
    Abstract: A method for identifying a compound for modulating the formation of 14,15-LTC4 (Eoxin C4; EoxC4), 14,15-LTD4 (Eoxin D4; EoxD4), or 14,15-LTE4 (Eoxin E4; EoxE4) in a biological system. A method for identifying a compound with an anti-inflammatory effect, the method comprising testing the compound for an effect on formation and/or activity of 14,15-LTC4 (Eoxin C4; EoxC4), 14,15-LTD4 (Eoxin D4; EoxD4), or 14,15-LTE4 (Eoxin E4; EoxE4) in a biological system. A method of making an anti-inflammatory composition or Eoxin formation-modulating composition comprising (i) identifying an anti-inflammatory compound or Eoxin formation-modulating compound by a method of the invention; (ii) combining the compound with a pharmaceutically acceptable excipient or carrier.
    Type: Application
    Filed: June 27, 2007
    Publication date: October 1, 2009
    Inventors: Hans-Erik Claesson, Magnus Bjorkholm
  • Patent number: 7592302
    Abstract: A process for producing powder, flakes, or pellets containing ?-sulfo fatty acid alkylester salt in high concentrations, the process including: (1) a step of preparing a paste containing ?-sulfo fatty acid alkylester salt; (2) a step of aging the thus obtained paste; (3) a step of making the aged paste into flakes or pellets containing equal to or less than 10 wt % of water and then optionally crushing the resulting flakes or pellets into a powder having an average particle diameter of 100-1500 ?m; and (4) a step of aging The powder, flakes, or pellets.
    Type: Grant
    Filed: June 11, 2004
    Date of Patent: September 22, 2009
    Assignee: Lion Corporation
    Inventors: Kensuke Itakura, Akitomo Morita, Masahiko Matsubara, Madoka Suwa, Taku Nishio
  • Patent number: 7585856
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: September 8, 2009
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Charles N. Serhan
  • Patent number: 7550613
    Abstract: Compounds of formula (I); wherein R1 and R2 are the same or different and may be selected from the group consisting of a hydrogen atom, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio group, an alkoxycarbonyl group, an alkylsulfinyl group, an alkylsulfonyl group, an amino group, and an alkylamino group; and X represents a carboxylic acid group, a carboxylate group, or a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex or pro-drug thereof, with the provisos that the compound of formula (I) is not (all-Z)-4,7,10,13,16,19-docosahexaenoic acid (DHA), alpha-methyl DHA, alpha-methyl DHA methyl ester, alpha-methyl DHA ethyl ester or alpha-hydroxy DHA ethyl ester, are disclosed. A fatty acid composition and a pharmaceutical composition comprising such compounds are also disclosed.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: June 23, 2009
    Assignee: Pronova Biopharma Norge AS
    Inventors: Morten Bryhn, Jan Kopecky, Anne Kristin Holmeide
  • Patent number: 7420071
    Abstract: There are provided novel thermally stable surfactants for use with fillers in the preparation of polymer composites and nanocomposites. Typically, surfactants of the invention are urethanes, ureas or esters of thiocarbamic acid having a hydrocarbyl group of from 10 to 50 carbons and optionally including an ionizable or charged group (e.g., carboxyl group or quaternary amine). Thus, there are provided surfactants having Formula I: wherein the variables are as defined herein. Further provided are methods of making thermally stable surfactants and compositions, including composites and nanocomposites, using fillers coated with the surfactants.
    Type: Grant
    Filed: May 4, 2005
    Date of Patent: September 2, 2008
    Assignee: UChicago Argonne, LLC
    Inventor: David J. Chaiko
  • Publication number: 20070292485
    Abstract: Disclosed are polyol esters comprising a polyol having at least one hydroxyl group esterified to at least one compound having a carboxyl group. Methods of making the polyol ester compounds are also disclosed. The invention also relates to feed compositions comprising polyol ester compounds.
    Type: Application
    Filed: June 18, 2007
    Publication date: December 20, 2007
    Applicant: Novus International Inc.
    Inventors: Stephen J. Lorbert, Thomas Frederick Blackburn, Charles S. Schasteen
  • Patent number: 7309721
    Abstract: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: December 18, 2007
    Assignee: Merck + Co., Inc.
    Inventors: Richard J. Budhu, George A. Doherty, Jeffrey J. Hale, Christopher L. Lynch, Sander G. Mills, William E. Neway, III
  • Patent number: 7303760
    Abstract: Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: December 4, 2007
    Assignees: Alza Corporation, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Samuel Zalipsky, Alberto Gabizon
  • Patent number: 7279563
    Abstract: A hydrocarbyldithiomethyl-modified compound of the Formula: R1—O—CH2—S—S—R2 or a salt thereof wherein R1 is an organic molecule and R2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl groups in organic molecules such as nucleotides. The hydrocarbyldithiomethyl-modified compounds can also be used for chemically synthesizing oligonucleotides and for sequencing nucleic acid compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: October 9, 2007
    Assignee: Helicos BioSciences Corporation
    Inventor: Marek Kwiatkowski
  • Patent number: 7253296
    Abstract: The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.
    Type: Grant
    Filed: February 12, 2004
    Date of Patent: August 7, 2007
    Assignee: Genfit
    Inventors: Raphaël Darteil, Karine Caumont-Bertrand, Jamila Najib
  • Patent number: 7235586
    Abstract: The invention relates to the use of cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and carbamoyloxy as therapeutic agents e.g. as ocular hypotensives. The compounds used in accordance with the invention are represented by the following formula I: wherein a wavy segments indicate either the alpha (?) or beta (?) configuration; the dashed bond represents a double bond or a single bond; U, Y, X, R1, Ar, n, x and y are as defined in the specification.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: June 26, 2007
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Robert M. Burk
  • Patent number: 7087770
    Abstract: A labile disulfide-containing compound under physiological conditions containing a labile disulfide bond and a transduction signal.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: August 8, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, Sean D. Monahan, Vladimir G. Budker, Paul M. Slattum, David B. Rozema
  • Patent number: 6991888
    Abstract: The present invention relates to a novel photoresist composition that can be developed with an aqueous alkaline solution, and is capable of being imaged at exposure wavelengths in the deep ultraviolet. The invention also relates to a process for imaging the novel photoresist as well as novel photoacid generators. The novel photoresist comprises a) a polymer containing an acid labile group, and b) a novel mixture of photoactive compounds, where the mixture comprises a lower absorbing compound selected from structure 1 and 2, and a higher absorbing compound selected from structure 4 and 5, where, R1 and R2 R5, R6, R7, R8, and R9 are defined herein; m=1–5; X? is an anion, and Ar is selected from naphthyl, anthracyl, and structure 3, where R30, R31, R32, R33, and R34 are defined herein.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: January 31, 2006
    Assignee: AZ Electronic Materials USA Corp.
    Inventors: Munirathna Padmanaban, Takanori Kudo, Sangho Lee, Ralph R. Dammel, M. Dalil Rahman
  • Patent number: 6984396
    Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: January 10, 2006
    Assignee: Alza Corporation
    Inventors: Samuel Zalipsky, Alberto A. Gabizon
  • Patent number: 6979460
    Abstract: A novel amphiphilic lipid compound having a cleavable, vinyl ether linked hydrophilic headgroup is described. Also described are liposomes containing the vinyl ether lipid compound, which may be triggered to release their contents and/or permeablize or fuse with target lipid membranes. The cleavable vinyl ether linkage allows the hydrophilic headgroup to be dissociated from the hydrophobic tailgroup(s) of the lipid compound to facilitate phase transitions in the lipid bilayer.
    Type: Grant
    Filed: July 17, 2000
    Date of Patent: December 27, 2005
    Assignee: Purdue Research Foundation
    Inventors: David H. Thompson, Jeremy A. Boomer, Robert Haynes
  • Patent number: 6936729
    Abstract: A labile disulfide-containing compound under physiological conditions, comprising: the disulfide-containing compound having a labile disulfide bond that is either a disulfide bond that is cleaved more rapidly than oxidized glutathione or a disulfide bond constructed from thiols in which one of the constituent thiols has a lower pKa than glutathione or a disulfide bond that is activated by intramolecular attack from a free thiol.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: August 30, 2005
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, Sean D. Monahan, Vladimir G. Budker, Paul M. Slattum, David B. Rozema
  • Patent number: 6906210
    Abstract: Processes for the preparation of R-lipoic acid or S-lipoic acid comprising a process step selected from a) distillation of dihydrolipoic acid, b) reaction of ?or its stereoisomer, where Ms is SO2—R? and R and R? independently of one another is [sic] C1-C6-alkyl, C3-C8-cycloalkyl, C3-C8-cycloalkylalkyl, aryl or aralkyl, with sodium sulfide and sulfur in ethanol and reaction with a complex hydride, (c) the extraction of a protic solution of R-dihydrolipoic acid or S-dihydrolipoic acid with organic solvents at a pH from 9 to 10, or (d) the extraction of R-dihydrolipoic acid or S-dihydrolipoic acid with organic solvents from a protic solution at a pH of 4 to 5, or a combination of one or more of steps (a) to (d), and processes for the preparation of dihydrolipoic acid and the compound 1,6,8 [lacuna] octanetriol.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: June 14, 2005
    Assignee: BASF Aktiengesellschaft
    Inventors: Martin Jochen Klatt, Markus Niebel, Joachim Paust
  • Patent number: 6831186
    Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Grant
    Filed: October 22, 2002
    Date of Patent: December 14, 2004
    Assignee: Schering Aktiengesellschft
    Inventors: John G Bauman, William J Guilford, John F Parkinson, Werner Skuballa, Babu Subramanyam
  • Publication number: 20040198995
    Abstract: A process for preparing acyloxybenzenesulfonates by reacting a carboxylic acid derivative with a salt of a phenolsulfonic acid in the presence of an antioxidant, preferably 2,6-di-tert-butyl-4-methylphenol. The addition of such antioxidants gives a product having a high color quality.
    Type: Application
    Filed: January 13, 2004
    Publication date: October 7, 2004
    Applicant: Clariant GmbH
    Inventors: Alexander Lerch, Michael Seebach, Wolf-Dieter Mueller
  • Publication number: 20040122236
    Abstract: The present invention is directed to compositions comprising lysophosphatidic acid analogs and methods of using such analogs as agonist or antagonists of LPA receptor activity. In addition the invention is directed to LPA receptor agonists that vary in the degree of selectivity at individual LPA receptors (i.e. LPA1, LPA2 and LPA3). More particularly the present invention is directed to LPA analogs wherein the glycerol is replaced with ethanolamine and a variety of substitutions have been linked at the second carbon atom.
    Type: Application
    Filed: October 15, 2003
    Publication date: June 24, 2004
    Inventors: Kevin R. Lynch, Timothy L Macdonald, Christopher E Heise, Webster L Santos, Mark D Okusa
  • Publication number: 20040116408
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Application
    Filed: August 12, 2003
    Publication date: June 17, 2004
    Inventor: Charles N. Serhan
  • Publication number: 20040044050
    Abstract: The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 &ohgr;-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases.
    Type: Application
    Filed: June 13, 2003
    Publication date: March 4, 2004
    Inventors: Daniel W. Goodman, Michael R. Hanley, Stuart L. Bursten
  • Patent number: 6657071
    Abstract: By conducting a sulfonation step for bringing a fatty acid alkyl ester into contact with a sulfonating gas in the presence of a coloring inhibitor to sulfonate the fatty acid alkyl ester, an esterification step for esterifying the product of the sulfonation step with a lower alcohol, a neutralization step for neutralizing the esterified product of the esterification step to obtain a neutralized product, a bleaching step for bleaching the neutralized product to obtain a bleached product, and preferably an optional deodorization step for deodorizing the bleached product, the production process can be simplified and &agr;-sulfofatty acid alkyl ester salts which have a pale color close to white and preferably have less odor can be obtained.
    Type: Grant
    Filed: December 13, 2001
    Date of Patent: December 2, 2003
    Assignee: Lion Corporation
    Inventors: Tetsuo Tano, Masahisa Yoshiya, Taku Nishio, Seiji Matoba, Yozo Miyawaki
  • Patent number: 6639088
    Abstract: A hydrocarbyldithiomethyl-modified compound of the Formula: R1—O—CH2—S—S—R2 or a salt thereof wherein R1 is an organic molecule and R2 is a hydrocarbyl is useful for protecting and/or blocking hydroxyl groups in organic molecules such as nucleotides. The hydrocarbyldithiomethyl-modified compounds can also be used for chemically synthesizing oligonucleotides and for sequencing nucleic acid compounds.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: October 28, 2003
    Assignee: Quiatech AB
    Inventor: Marek Kwiatkowski
  • Publication number: 20030069435
    Abstract: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
    Type: Application
    Filed: June 20, 2002
    Publication date: April 10, 2003
    Inventor: Charles N. Serhan
  • Publication number: 20030054028
    Abstract: Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the therapeutic agent in its original form. The linkage is stable under nonreducing conditions. The conjugate can be incorporated into liposomes for administration in vivo and release of the therapeutic agent in response to endogeneous in vivo reducing conditions or in response to administration of an exogeneous reducing agent.
    Type: Application
    Filed: January 25, 2002
    Publication date: March 20, 2003
    Applicant: Alza Corporation
    Inventors: Samuel Zalipsky, Alberto A. Gabizon
  • Patent number: 6441036
    Abstract: The present invention relates to novel fatty acid analogous of the general forumla I: CH3—[CH2]m—[xi—CH2]n—COOR, as defined in the specification, which can be used for the treatment and/or prevention of obesity, fatty liver and hypertension. Further, the invention relates to a nutritional composition comprising such fatty acid analogues, and a method for reducing the total weight, or the amount of adipose tissue in an animal. The invention also relates to a method for improving the quality of product such as meat, milk and eggs.
    Type: Grant
    Filed: January 27, 2001
    Date of Patent: August 27, 2002
    Assignee: Thia Medica AS
    Inventor: Rolf Berge
  • Publication number: 20020115769
    Abstract: Aromatic and aliphatic organic thiol compounds are disclosed which can be utilized to plasticize and/or stabilize halogen-containing polymer compositions, especially poly(vinyl chloride) compositions. Compounds of the present invention are utilized in polymers normally susceptible to deterioration and color change, which typically occurs during processing of the polymer or exposure to certain environments.
    Type: Application
    Filed: June 19, 2001
    Publication date: August 22, 2002
    Applicant: THE COLLEGE OF WILLIAM & MARY
    Inventors: William Herbert Starnes, Bin Du